New Data On Breast Imaging Using Cardiolite(R) To Be Presented At ASCO Breast Cancer Symposium

Lantheus Medical Imaging, a worldwide leader in diagnostic imaging, announced that the company's leading imaging agent, Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) will be featured in a new study on molecular breast imaging being presented on Sunday, September 7, 2008, at 7:00am -12:00pm (EDT) as part of the poster sessions (abstract #68) at the American Society of Clinical Oncology's 2008 Breast Cancer Symposium in Washington, DC.

"This promising new study on molecular breast imaging provides encouraging data for millions of women and families who are impacted by breast cancer and sheds light on potential new diagnostic approaches for finding tumors in women who have dense breast tissue, which can confound mammograms," stated Don Kiepert, president and chief executive officer of Lantheus Medical Imaging. "We are proud to supply the imaging agent for this important clinical effort. Breast cancer is a devastating disease and we recognize how important and valuable early detection is for women."

source: Lantheus Medical Imaging